Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Sponsor: AstraZeneca
A PHASE2 clinical study on Head and Neck Cancer and Head and Neck Neoplasms, this trial is ongoing. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Jan 2026 — Present [monthly]
Unknown PHASE2
Status: Active Not Recruiting → Unknown
-
Sep 2024 — Jan 2026 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Nov 2022 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Dec 2021 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Dec 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Dec 2018 — Dec 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Trisha Wise-Draper
For direct contact, visit the study record on ClinicalTrials.gov .